Despite its removal from the market in the United States, the anti-CD33 antibody with which most experience developed, gemtuzumab ozogamicin, has recently been tested in low doses during induction and consolidation chemotherapy for AML and has been found to result in superior overall and disease-free survival when used in combination with chemotherapy (Castaigne et al., 2012). Here, CD33 is linked to acute myeloid leukemia.